Article Details

FDA approves first biosimilar to top-selling eye drug Lucentis | BioPharma Dive

Retrieved on: 2021-09-20 16:50:55

Tags for this article:

Click the tags to see associated articles and topics

FDA approves first biosimilar to top-selling eye drug Lucentis | BioPharma Dive. View article details on hiswai:

Excerpt

Byooviz is the second biosimilar to be approved in the U.S. in 2021 after the agency cleared Mylan and Biocon's Semglee as interchangeable with Sanofi's Lantus.

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up